

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-0435US1	Application No. 10/521,325
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Bonnert et al.	
		Filing Date August 15, 2005	Group Art Unit 1626

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2006-0111426	05/25/2006	Bonnert et al.			
	2	2008-0249110	10/09/2008	Bonnert et al.			
	3	2006-0264444	11/23/2006	Bonnert et al.			
	4	2008-0027092	01/31/2008	Bonnert et al.			
	5	2008-0051586	02/28/2008	Keegan et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	6	WO 01/032621	05/10/2001	WIPO			Abstract	
	7	WO 03/101961	12/11/2003	WIPO				
	8	WO 03/101981	12/11/2003	WIPO				
	9	WO 2004/007451	01/22/2004	WIPO				
	10	WO 2004/106302	12/09/2004	WIPO				
	11	WO 2005/019171	03/03/2005	WIPO				
	12	WO 2005/040114	05/06/2005	WIPO				
	13	WO 2005/054232	06/16/2005	WIPO				
	14	WO 2006/075139	07/20/2006	WIPO				
	15	WO 2007/138282	12/06/2007	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	16	Morissette et al., "High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids", <i>Advanced Drug Delivery Reviews</i> 56:275-300 (2004)
	17	Patani and LaVoie, "Bioisosterism: A Rational Approach in Drug Design", <i>Chem Rev.</i> 96:3147-3176 (1996)
	18	
	19	
	20	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	